Marc A Schuckit

Title: The Innovative Contributions of Marc A. Schuckit

Introduction

Marc A. Schuckit, an accomplished inventor based in Del Mar, California, has made significant strides in the field of biomedical research. He is recognized for his pioneering work related to the human GABA neurotransmitter receptor, contributing to our understanding of genetics and pharmacology.

Latest Patents

Schuckit holds a notable patent titled "Polynucleotides Encoding Polymorphic Human GABAA Receptor α-6 Subunit." This patent encompasses compositions and methods based on a specific polymorphism in the gene encoding the α6 subunit of the human GABA neurotransmitter receptor. Importantly, this polymorphism results in the substitution of a serine residue for a proline residue at amino acid position 385 of the α6 polypeptide sequence, which is crucial for receptor functioning. Remarkably, this genetic variation is associated with reduced sensitivity to ethanol and benzodiazepine drugs, indicating significant implications for pharmacological treatments.

Career Highlights

Marc A. Schuckit is affiliated with the United States of America as represented by the Secretary of the Department of Health and Human Services. His ongoing research and innovative spirit continue to influence advancements in medical and therapeutic applications.

Collaborations

Throughout his career, Schuckit has worked alongside distinguished colleagues, including David Goldman and Nakao Iwata. Their collaborations have bolstered the research and development of groundbreaking approaches aimed at better understanding the genetic factors affecting drug sensitivity and dependency.

Conclusion

Marc A. Schuckit's contributions to the scientific community through his patent and collaborative efforts underline the importance of innovation in addressing complex biological challenges. His work has the potential to enhance therapeutic strategies and improve patient outcomes in the field of medicine.